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Differential profiling of lacrimal 
cytokines in patients suffering from 
thyroid-associated orbitopathy
Edina Kishazi1, Marianne Dor1, Simone Eperon2, Aurélie Oberic2, Natacha Turck1 & 
Mehrad Hamedani2
The aim was to investigate the levels of cytokines and soluble IL-6R in the tears of patients with 
thyroid-associated orbitopathy (TAO) disease. Schirmer’s test was adopted to collect tears from TAO 
patients (N = 20, 17 women, mean age (±SD): 46.0 years (±13.4)) and healthy subjects (N = 18, 10 
women, 45.4 years (±18.7)). Lacrimal cytokines and soluble IL-6R (sIL-6R) were measured using a 10-
plex panel (Meso Scale Discovery Company) and Invitrogen Human sIL-6R Elisa kit, respectively. Tear 
levels of IL-10, IL-12p70, IL-13, IL-6 and TNF-α appeared significantly higher in TAO patients than in 
healthy subjects. Interestingly, IL-10, IL-12p70 and IL-8 levels increased in tears whatever the form of 
TAO whereas IL-13, IL-6 and TNF-α levels were significantly elevated in inflammatory TAO patients, 
meaning with a clinical score activity (CAS) ≥ 3, compared to controls. Furthermore, only 3 cytokines 
were strongly positively correlated with CAS (IL-13 Spearman coeff. r: 0.703, p = 0.0005; IL-6 r: 0.553, 
p = 0.011; IL-8 r: 0.618, p = 0.004, respectively). Finally, tobacco use disturbed the levels of several 
cytokines, especially in patient suffering of TAO. The differential profile of lacrimal cytokines could be 
useful for the diagnosis of TAO patients. Nevertheless, the tobacco use of these patients should be 
taken into account in the interpretation of the cytokine levels.
Thyroid-associated orbitopathy (TAO) is an autoimmune disorder, very often related to Graves’ disease. Clinical 
manifestations are mainly proptosis (eye protrusion), lid retraction and eye movement limitation with diplopia. 
During the acute phase, there are some inflammatory signs such as lid edema, conjunctival edema (chemosis), 
redness of the eye or lids1,2. These clinical signs permit the scoring of the inflammatory process (Clinical Activity 
Score, CAS) and the monitoring of patients under anti-inflammatory treatment3. Smoking is considered as a main 
risk factor for TAO disease. It has been shown that patients with more severe eye disease are more likely to be 
smokers, than those with less severe or no disease4.
The diagnosis of Graves’ disease is based on the detection of circulating auto-antibodies against thyroid stim-
ulating hormone receptor (TSHR) in patient’s blood. Concerning the orbitopathy, there is no specific biomarker 
available at the moment.
TAO may occur (5–10% of cases) before any thyroid dysfunction and without any detectable auto-antibodies2. 
That is why a specific biomarker of the orbital disease would be very useful for the diagnosis and the follow-up 
of the patients.
Tears could be a relevant source of biomarker because of the proximity of the inflammatory process and 
the frequent involvement of lacrimal gland in TAO5. Furthermore, collection of tears is easy and non-invasive 
(Schirmer’s paper).
Despite the progress done in the understanding of TAO disease, some important pieces are still missing. 
Nevertheless, the target cells seem to be the fibroblasts presenting the thyroid stimulating hormone receptor 
(TSHR)6–9. They display surface receptors for cytokines what render them as potential target for the immune sys-
tem. Several cytokines have been shown to be present in serum10–14, in orbital fat and muscles15–17, and tears18,19 of 
patients suffering from TAO. Cytokines could be used as potential biomarkers since they are identified as major 
actors in the TAO disease.
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The goal of our study is to measure the levels of 10 cytokines (Interferon- γ (IFN-γ), interleukins IL-10, 
IL-12-p70, IL-13, IL-1β, IL-2, IL-4, IL-6, IL-8, Tumor necrosis factor-α (TNF-α) and soluble Interleukin-6 recep-
tor (sIL-6R)) in TAO patients’ tears compared to control subjects. Potential correlations between the levels of 
these cytokines and the clinical features of TAO patients were also investigated. Considering that smoking has 
a negative impact on the evolution of TAO, we finally observed its potential influence on cytokines and sIL-6R.
Results
Our study included 20 TAO patients (17 women) with a mean age of 46.0 years (±13.4) and 18 healthy subjects 
(10 women) with a mean age of 45.4 years (±18.7). No significant difference was observed between age and gen-
der of these 2 groups. 14 out of 20 TAO patients had a more active form of the disease (with a CAS ≥ 3). 9 TAO 
patients were active tobacco consumers at the time of the tear collection apart from one person, who stopped a 
couple of weeks before, but was still considered as a smoker. Among control subjects, 6 were active tobacco con-
sumers. The demographic and clinical data describing TAO and control patients are presented in Table 1.
Cytokines and sIL-6R concentrations in tears of TAO and control patients. The lacrimal concen-
tration of 10 cytokines and sIL6-R in TAO patients and control subjects are shown in Fig. 1 (details of the cytokine 
concentrations can be found in Supplementary Information S1). All molecules tended to be more concentrated in 
TAO patients than in control patients, except for IFN-γ, for which control tears showed a slightly more elevated 
level. The concentrations of 5 cytokines (IL-10, IL-12p70, IL-13, IL-6 and TNF-α) appeared significantly higher 
in TAO patients than in control subjects.
Detailed analyses showed that IL-10, IL-12p70 and IL-8 levels were significantly elevated whatever the form 
of TAO (CAS < 3 and CAS ≥ 3, Fig. 2 and Supplementary Information S2). The IL-13, IL-6 and TNF-α were sig-
nificantly elevated in TAO patients with CAS ≥ 3 compared to controls. Nevertheless, none of the cytokines was 
able to distinguish between patients with mild form of TAO and control subjects. At the opposite, sIL6- R levels 
could discriminate patients with mild form of TAO and control subjects (p = 0.016) but not patients with more 
severe form of TAO and control patients.
Tear cytokine concentrations correlation with CAS in TAO patients. Cytokine concentrations were 
therefore evaluated according to their potential relationship with the activity of the disease (Fig. 3). The IL-13, 
IL-6 and IL-8 cytokines were strongly positively correlated with the activity of the disease (CAS) (Spearman coeff. 
r: 0.703, p = 0.0005; r: 0.553, p = 0.011; 0.618, p = 0.004, respectively). Furthermore, we dichotomised patients 
according to their CAS (moderate to severe inflammatory form when CAS ≥ 3 and mild inflammatory form for 
CAS < 3) and compared their cytokine concentrations in tears (Fig. 3). The group with a CAS ≥ 3 showed a sig-
nificant up-regulation in the concentration of IL-6 (p-value = 0.023) and IL-8 (p-value = 0.006).
Tear cytokine concentrations and smoking status in TAO and control patients. We investigated 
tear cytokine concentrations in patient’s grouping according to their smoking status (smokers vs. non-smokers 
after grouping patients according to their pathology). In control subjects, no significant difference was observed 
between non-smokers and smokers control subjects (details can be found in Supplementary Information S3). 
On the opposite, in tears of TAO patients, 3 cytokines exhibited significantly more elevated levels in 
non-smoker patients (Fig. 4 and Supplementary Information S3) compared to smokers (IL-6: p-value = 0.012, 
IL-8: p-value = 0.025, TNF-α: p-value = 0.022). Then, we grouped all subjects according to their tobacco use 
(Supplementary Information S4). Tears of TAO smokers presented higher levels of IL-4 compared to tears of 
control smokers (p = 0.016, Supplementary Information S4). Furthermore, in the non-smokers group, IL-10, 
IL-12p70, IL-13, IL-6, IL-8 and TNF-α were significantly increased in TAO patients versus control non-smokers.
Controls TAO p-value*
Gender (M/F) 8/10 3/17 0.074
Age (mean ± SD) years 45.4 ± 18.7 46.0 ± 13.4 0.939
Eye (Left/Right) 8/10 10/10 0.757








Table 1. Demographic description of the study cohort. The number of TAO patients showing a clinical activity 
score (CAS) from 0 to 5 are indicated. N.A: Not Applicable; M: male/F: female; SD: Standard deviation; CAS: 
Clinical Activity Score; *Fischer tests for categorical variables and Mann-Whitney U tests for continuous 
variables.
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Discussion
Thyroid-associated orbitopathy (TAO) is the common ‘extra-thyroid’ manifestation of Graves’ disease. This is an 
autoimmune disorder in which specific auto-antibodies bind and target orbital fibroblasts that release chemok-
ines leading to infiltration of lymphocytes. Through a variety of mechanisms, activated orbital fibroblasts produce 
therefore significant inflammation, oedema and fat deposition resulting in increased orbital volume and therefore 
characteristic eye protrusion (exophthalmos or proptosis) usually observed in TAO disease.
In this context, the general mechanism leading to the pathological event has been largely elucidated, with a 
key place occupied by inflammatory cytokines and chemokines. Investigating their levels in tears of TAO patients 
could be therefore particularly informative of the clinical status of the TAO patients. Indeed, tears emerge as 
promising fluid for the discovery of biomarkers and for better understanding diseases, especially for those which 
could lead to ocular manifestations. The relatively low volume available after collection is counter-balanced by 
high protein concentration and the sensitivity of multiplexing ELISA. Several studies on ocular or associated 
diseases have already demonstrated the presence of elevated inflammatory cytokines in tears5,18–22. Furthermore, 
as lacrimal glands can be affected by TAO disease5,23,24, tears could be a central actor, but not deeply studied yet 
in this context.
The regulation of the inflammation, an important process of the TAO disease, is subtly mediated by cytokines 
and chemokines that can be naively classified into pro and anti- inflammatory components. Nevertheless, several 
of them present pleiotropic functions depending on stimuli or environment. The 10-plex chosen to investigate 
the tears of TAO patients contained a mix of pro and anti-inflammatory cytokines. Our study showed net lacri-
mal elevation of these cytokines in TAO patients compared to healthy subjects, but only the increases of IL-10, 
IL-12p70, IL-6, IL-13 and TNF-α were significant. Furthermore, IL-12p70, IL-10 and IL8 levels were higher 
whatever the subtypes of TAO considered and IL-6, IL-13 and TNF-α seemed to be more expressed in patients 
presenting the more active phase of TAO.
Figure 1. Cytokine concentrations in tears of TAO patients versus those of control patients (pg/ml). *Mann-
Whitney U tests, p-values (bold data highlight significant p-values). For esthetical reason, the point of one TAO 
patient was removed for TNF-α, as he had a concentration much higher than the other patients (193.20 pg/ml).
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Globally, our findings obtained for TNF-α, IL-6, IL-8 IL-10 and IL-13 were completely relevant of TAO and 
confirmed previous studies on tears5,18,19 but also on serum19–22,25. They also confirmed some results that we 
obtained performing quantitative proteomics analyses with mass spectrometry26. Our major result was that two 
proteins related to the inflammation, cystatin C and serpin A3, were found significantly upregulated in tears of 
TAO patients compared to controls (ratio TAO/controls = 1.53 for cystatin and 1.7 for serpinA3). This is fully in 
line with the cytokine level increases that we observed in the current article between TAO patients and healthy 
controls. Indeed, IL-6 is one of the major regulator of serpinA327, found as a stimulus of the synthesis and secre-
tion of this protein28. Concerning cystatin C, TNF-α was shown to upregulate its expression while IL-10 is sup-
posed to decrease it29. The fact that cystatin C was found upregulated despite an upregulation of IL-10 may imply 
that the upregulation power of the TNF-α is greater than the downregulation power of IL-10 on the cystatin C 
expression. This duality may also be the reason why cystatin C was found with a lower upregulated ratio in TAO 
patients (1.53) compared to serpinA3 (1.7). The global conclusion of the two parts of our study is that the inflam-
matory process appeared as the main deregulated pathway in TAO disease and could be, both at cytokine and 
protein levels, a very promising target for better management of the patients.
In addition, TNF-α, IL-6, IL-8 IL-10 and IL-13 have already been described for various involvements in TAO. 
These include (i) stimulation of the glycosaminoglycan production in vitro in ocular fibroblast for TNF-α30,31, (ii) 
secretion by orbital fibroblasts under the stimulation of TSHR antibodies or prostaglandin E2 for IL-632–34, (iii) 
expression by fibrocytes that can induce the infiltration of inflammatory cells and subsequent tissue remodelling 
for IL-835 and the steroid treatment which decreases its expression level for IL-822 and (iv) regulation of both T 
and B-cells functions for IL-1036. Finally, for all of them, genetic polymorphism of their gene in relation with TAO 
have been identified in different populations21,37–44.
By comparison with the previous cytokines described, IL-12p70 (shortly called IL-12) is few investigated in 
TAO to date. Nevertheless, its expression is induced by TSHR and CD4045,46. Serum elevation of IL-1247 and pol-
ymorphism association have been reported in TAO patients45.
Figure 2. Cytokine concentrations (pg/ml) in tears of control subjects, patients showing a CAS < 3 and patients 
showing a CAS ≥ 3. *Mann-Whitney U tests, p-values (bold data highlight significant p-values).
www.nature.com/scientificreports/
5SCIENTIFIC REpoRts |  (2018) 8:10792  | DOI:10.1038/s41598-018-29113-2
Interestingly, TNF-α, IL-12p70, IFN-γ and IL-2 belong to the cytokines T Helper 1 (Th1) that mediate the 
development of organ-specific autoimmune disease and are considered as positive effectors of inflammation. 
However, in our study, IFN-γ and IL-2 did not display the same pattern as IL-12p70 and TNF-α. No significant 
variation was observed for them in our study. Even if these results are surprising regarding the potential role of 
IFN-γ in the pathogenesis of TAO, similar results were nevertheless previously reported in blood48–50. The low 
percentage of samples above the limit of detection could be another explanation. Concerning IL-2, controversial 
data exist18,20,21,51,52 and at this stage, our data cannot confirm or dismiss these preliminary findings.
At the opposite, IL-10, IL-13 and IL-6 are produced by Th2 cells. The involvement of both CD4+ T cell popu-
lations is described in TAO disease53–56. Their predominance seems tissue-specific: Th1 cells are more detected in 
extracellular muscles whereas Th2 cells are located preferably in orbital tissues. Moreover, their importance seems 
to be course-dependent: Th1 cells are present in active phase and Th2 in inactive phase57.
Smoking has been shown to greatly influence TAO58,59. As expected we observed disturbed levels of some 
cytokines in patients suffering from this disease. The TNF-α, IL-6, IL-8 cytokines seemed particularly affected 
by the smoking status of patients. They appear significantly down-regulated in smokers as compared to 
non-smokers. The recording of this information is therefore crucial in the management of the TAO patients and 
can be taken into consideration for the interpretation of the biological parameters in these patients. This result 
raises also a point that remains too often ignored concerning the influence of interfering factors on cytokine 
measurements. A steroid effect has been speculated60–63 without being clearly studied and could be particularly 
pertinent in ocular diseases in which steroids treatment is often administrated. Other factors could be interesting 
to investigate including patient parameter (such as age64–66, physical activity67–69, diet70–72) but also pre-analytical 
sampling (time of collection, storage, stability in different biological fluids)73,74 and even co-existing diseases. That 
may become even more likely if tears are considered as the biological fluid because not so much information are 
also available concerning its variability and a lot of studies remain to be done for establishing all the knowledge 
Figure 3. Cytokine concentration (pg/ml) in tears of TAO patients according to their CAS. P-values on the top 
of the figure relates to comparison between patients presenting CAS ≥ 3 and patients presenting CAS < 3. On 
the left of the figure, Spearman correlation (r) and its p-value are indicated.
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required for its routine clinical use. This point has to be solved by robust multi-centric studies before proposing 
to daily use of cytokines measurements. In addition, as no standardisation procedure exists, multiple bioassays 
or immunoassays platforms (Luminex, Mescoscale, single array, microarray) have been also used for quantifying 
cytokines. This technological variability induces therefore different sensitivity, specificity, accuracy and makes 
therefore very difficult comparison between the few studies existing in tears. Indeed, the dynamic range of con-
centration reported for control subjects are different from one study to another5,18,19 and ours is not an exception. 
This can also explain why some data appear controversial in the cytokines studies.
Two other studies from Huang et al.5,18 and one from Ujhelyi et al.19 also measured some cytokines in the 
context of TAO diseases, in similar cohorts of patients. While we confirmed some of their results (upregulation 
of TNF-α, IL-6 and IL-13 in TAO patients), our work permitted to highlight IL 12-p70 as a promising cytokine 
but also some non-concordant results between their studies and our (for IL-1β, IL-2 and IL-8). Moreover, by 
taking into account the smocking statue, we opened the question of how this parameter needs to be considered 
in clinical investigations. All these points clearly established the need to deeper explore the cytokine question for 
TAO disease.
Some limitations in this investigation have to be mentioned. The sample size is relatively small, probably mask-
ing significant results. It is nevertheless in the traditional size of cohort reported for this disease. Considering the 
sample size of our subgroups (smocking status and CAS), we are aware that these data have to be carefully taken 
Figure 4. Cytokine concentrations (pg/ml) in tears of TAO patients (T) and control subjects (C), comparing 
subgroups of smokers and non-smokers. *Mann-Whitney U tests, p-values (bold data highlight significant 
p-value).
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into account. However, it constitutes a first step to go deeper in the investigation of TAO disease. In addition to 
the size, only few but crucial clinical information has been collected, limiting the possibility to go deeper in the 
analyses (for example correlation between the levels of thyroid antibodies and cytokines cannot be studied). 
Introducing in the future studies, a group of Graves’ disease without orbitopathy could be also clinically pertinent. 
Regarding the technical part, we were limited by the sensitivity of the ELISA kits. It leaded to more or less high 
percentages of out of detection values for both TAO patients (from 0% of out of detection values for IL-8 to 75% 
for IFN-γ; mean = 30%) and controls (from 0% for IL-8 to 94% for IL-13; mean = 52%). However, we observed 
that in general we have a higher percentage of out of range for controls compared to TAO patients, which could be 
related to the fact that all the 11 molecules seemed to be in lower concentration among controls.
Overall, this study indicated that (i) elevated levels of cytokines can be observed in TAO patients and (ii) 
correlation exist with the activity of the disease but their levels could be influenced by the smoking status. 
Nevertheless, even if their use for TAO diagnosis or prognosis remains purely speculative at this stage, the obser-
vation of their elevations, decrease or stable levels could help to better understand this complex disease and 
therefore better manage patients.
Methods
Sample collection. Subjects > 18 years old were recruited at the Jules-Gonin Eye Hospital (Lausanne, 
Switzerland) between December 2013 and July 2015. Written informed consent was obtained from all subjects 
and the study was carried out according to the ethical standards (Declaration of Helsinki). The cantonal ethics 
committee for research on human beings has approved the patient’s informed consent form and the use of bio-
logical material (Human Research Ethics Committee in Lausanne, No 204/14, July 2014, Annex 2). We included 
20 TAO patients who did not suffer from any other ocular pathology and 18 control subjects who did not suffer 
from any systemic or ocular pathology, or suffered from a benign pathology such as ptosis or blepharochalasis. 
Assessing classical tests used in ophthalmology, patients with dry eye syndrome were excluded from the two 
groups to avoid any effect of ocular surface disorder on our results75. The Dry Eye WorkShop (2007)76 advice a 
cut-off value of ≤ 5 mm in 5 minutes in order to diagnosis dry eye subjects. All our patients gave more than 5 mm 
wetting in 3 minutes so we reduced the collection time to 3 minutes. In addition to the Schirmer test, dry eye diag-
nosis was done using ocular surface fluorescein staining method, following classical protocol. Patients wearing 
lenses and pregnant women were also excluded. Among the collected samples, 10 out of the 18 controls and 6 out 
of the 20 TAO patients were also used in the proteomics study that we carried in parallel26.
A sheet form was filled for each patient, summarising the demographic data and recording its medical history, 
both general and ocular anamnesis and smoking status. Indeed, since smoking negatively affects the course and 
severity of TAO, we differentiated between non-smokers and smokers.
To measure the inflammatory activity of the disease1,77, we recorded, for each eye, the clinical activity score 
(CAS), which is the sum of 7 items present; spontaneous retrobulbar pain, pain on attempted up or down gaze, 
swelling of the eyelids, redness of the eyelids, redness of the conjunctiva, conjunctival oedema and inflammation 
of the caruncle. The CAS cut-off at 3 discriminates between the mild inflammatory form of the disease and the 
moderate to severe form of the disease. A CAS ≥ 3 suggests initiating an immunosuppressive treatment.
Schirmer paper strips (Biotech Vision Care PVT LTD, Gujarat, India) were placed inside the lower eyelid 
of patient’s both eyes during a maximum of 3 minutes. A mean wetting of 19.5 ± 4.3 mm (range: 13–30 mm) 
was obtained in 3 min for healthy control subjects and 19.1 ± 5.9 mm (range: 10–30 mm) for TAO patients. No 
anaesthetics or eye drops were used before sample collection. After collection, the strip was inserted in a tube on 
ice and centrifuged at 7840 g for 7 min at 4 °C without any additional buffer, as described elsewhere78,79, and then 
immediately frozen at −80 °C. Both eyes were collected for each subject but were not pooled, and only one out of 
the two was used for further analyses. Concerning the eye selection, the main criterion was the CAS. We tried to 
have a majority of CAS ≥ 3, however when the two eyes of a TAO patient had a CAS < 3, we chose the eye with 
the higher CAS for further analyses. For controls, eye selection was done in order to homogenise both age and sex 
according to the TAO patient selection.
Cytokine measurement. Cytokine measurement was done using the multiplex Human Pro-inflammatory 
Panel 1 from Meso Scale Discovery company (lot: K0080448, catalogue number: K15049-D1, Rockville, MD, 
USA). The multiplex ELISA kit contains Interferon- γ (IFN-γ), IL-10, IL-12p70, IL-13, IL-1β, IL-2, IL-4, IL-6, 
IL-8, Tumor necrosis- α (TNF-α) spotted per well as a sandwich ELISA. Regarding the user manual, median 
lower limit of detection were the following: IFN-γ = 0.2 pg/ml, IL-10 = 0.03 pg/ml, IL-12p70 = 0.11 pg/ml, 
IL-13 = 0.24 pg/ml, IL-1β = 0.04 pg/ml, IL-2 = 0.09 pg/ml, IL-4 = 0.02 pg/ml, IL-6 = 0.06 pg/ml, IL-8 = 0.04 pg/
ml and TNF-α = 0.04 pg/ml. Minor changes were made to the original protocol provided by manufacturer, as 
follows: tear samples were diluted 50 times, limited volumes (25 µl instead of 50 µl) of samples were added in 
each well of the 96-well plate and incubated 2 hours at room temperature. After 3 washing steps, incubation with 
the capture antibody was carried out 2 hours at room temperature followed by an overnight incubation at 4 °C 
in order to improve the sensitivity of the assay. The plate was washed then 3 times and the read buffer containing 
electroluminescent SULFO-TAG labelled detection antibody was added. The 96-well plate was read on MSD 
Sector Imager (Rockville, MD, USA) which measures the light emitted upon applied voltage. The data were ana-
lysed with Discovery Workbench 4.0. software (Rockville, MD, USA).
Soluble Interleukin-6 receptor (sIL-6R) measurement. Soluble IL-6R was measured using Invitrogen 
Human sIL-6R Elisa kit (supplied by Thermofischer, Catalogue number: #KHR0061, Waltham, MA, USA), which 
is a colorimetric assay. Regarding the user manual, the analytical sensitivity of the kit was <8 pg/ml. The assay was 
carried out according to the manufacturer’s instructions, except that tears were diluted 50 times and incubation 
with the capture antibody was carried out overnight. The plate was read on Filtermax F3 Multi-mode microplate 
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reader (Molecular Devices, Sunnyvale CA, USA), and the data were analysed by Softmax Pro Microplate reader 
(Molecular Devices, Sunnyvale, CA, USA) and the associated- analysis software (version 6.2).
For cytokine and sIL-6R measurements, samples were tested in duplicate using 1 µl of sample per well. Means 
of the calculated concentrations were used for comparison and statistical analyses and the coefficient of variation 
was in the expected range of the assays.
Statistics. Statistical analysis and graphs were carried out in GraphPad Prism (version 7.02, GraphPad 
Software, Inc., La Jolla, CA, USA). As the distribution of the data didn’t follow Gaussian distribution, nonpara-
metric Mann-Whitney U-test was used for 2 group comparisons (or Kruskal-Wallis test if more groups were con-
sidered). A two-tailed p-value smaller than 0.05 was considered as significant. Spearman correlation coefficient 
between cytokine concentration and CAS was also calculated using this software. For all cytokines, out of range 
values were set as “zero”, in order to perform statistical analyses without losing information.
Data availability statement. The datasets generated during and/or analysed during the current study are 
available from the corresponding author on reasonable request.
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